U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07662785) titled 'Topical 2% Simvastatin for Xanthelasma Palpebrarum' on June 17.
Brief Summary: This study is evaluating whether a topical cream containing 2% simvastatin can improve xanthelasma palpebrarum, a common condition that causes yellow cholesterol deposits on the eyelids. Current treatments such as surgery, laser therapy, and chemical treatments can be effective but may cause scarring, pigment changes, or recurrence.
In this randomized, double-blind, vehicle-controlled trial, 30 adults with xanthelasma will be assigned to receive either topical 2% simvastatin cream or an identical inactive vehicle cream for 24 weeks. Neither participants ...